Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies. Patients at least six months post transplant were treated with deferasirox at a starting dose of 10 mg/kg/day for 52 week...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Carlos Vallejo, Montserrat Batlle, Lourdes Vázquez, Carlos Solano, Antonia Sampol, Rafael Duarte, Dolores Hernández, Javier López, Montserrat Rovira, Santiago Jiménez, David Valcárcel, Vicente Belloch, Mónica Jiménez, Isidro Jarque
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Ferrata Storti Foundation 2014-10-01
Edice:	Haematologica
On-line přístup:	https://haematologica.org/article/view/7174
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!